<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="199">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04710381</url>
  </required_header>
  <id_info>
    <org_study_id>FNO-IMUNOR-2020</org_study_id>
    <nct_id>NCT04710381</nct_id>
  </id_info>
  <brief_title>IMUNOR® Preparation in the Prevention of COVID-19</brief_title>
  <official_title>Pilot, Monocentre, Phase-IV Clnical Trial Assessing the Clinical Effect of Per Oral Immunomodulation Treatment Using the IMUNOR® Preparation in the Prevention of COVID-19 Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Ostrava</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to achieve prevention of COVID-19 disease in healthcare professionals&#xD;
      with administration of the IMUNOR® preparation, and decreasing the symptoms should the&#xD;
      disease appear.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective study is designed to collect data for evaluation of the preventive and&#xD;
      therapeutic effect of the IMUNOR® preparation, which is commonly used to treat patients with&#xD;
      laboratory or clinical manifestations of immunity disorders. Administration of&#xD;
      immunomodulation treatment will be based upon a willing informed consent with the&#xD;
      administration of the drug and based upon random selection. The study subjects will receive&#xD;
      IMUNOR® preventively; the anticipated preventive effect when using one packing (4 vials) is 6&#xD;
      weeks, and 12 weeks when using two packings. Should any signs of acute illness appear&#xD;
      (increased body temperature, cough, loss of smell and taste, etc.), a treatment dose of&#xD;
      IMUNOR®, i.e. 1 vial/day (total of 4 vials) will be administered immediately. Monitoring of&#xD;
      individual patients will take 6 weeks (1 packing) or 12 weeks (2 packings) from the beginning&#xD;
      of IMUNOR® administration. The clinical condition of study subjects will be monitored on a&#xD;
      daily basis. At the same time, possible onset of symptoms will be recorded.&#xD;
&#xD;
      The obtained data will be compared with a control group consisting of patients followed by&#xD;
      the Department of Preventive 'Medicine, University Hospital Ostrava.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study treatment (IMUNOR) will be administered to one group of study subjects only.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking will be used in the study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of COVID-19 disease</measure>
    <time_frame>6 or 12 weeks</time_frame>
    <description>The incidence of COVID-19 disease among the studied population will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevention of hospitalisations due to COVID-19</measure>
    <time_frame>6 or 12 weeks</time_frame>
    <description>The number of study subjects requiring hospitalisation due to COVID-19 will be observed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of sick-leave episodes</measure>
    <time_frame>6 or 12 weeks</time_frame>
    <description>The number of study subjects requiring a sick-leave due to COVID-19 will be observed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>IMUNOR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects in this arm will receive IMUNOR preparation as prevention against COVID-19 disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMUNOR</intervention_name>
    <description>The intervention consists of the administration of IMUNOR as prevention against COVID-19 disease</description>
    <arm_group_label>IMUNOR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Study subjects 18-60 years old&#xD;
&#xD;
          -  Ability to cooperate upon the study and to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any other immunomodulation treatment one month prior to enrolment and in the&#xD;
             course of the study&#xD;
&#xD;
          -  Acute disease of the cardiovascular, urogenital, respiratory or nervous system&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaromír Bystroň, Ass.Prof.,MD,CSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Ostrava</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiří Hynčica</last_name>
    <phone>0042059737</phone>
    <phone_ext>2587</phone_ext>
    <email>jiri.hyncica@fno.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <state>Moravian-Silesian Region</state>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Jiří Hynčica</last_name>
      <phone>0042059737</phone>
      <phone_ext>2587</phone_ext>
      <email>jiri.hyncica@fno.cz</email>
    </contact>
    <investigator>
      <last_name>Jaromír Bystroň, Ass.Prof.,MD,CSc.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid19</keyword>
  <keyword>prevention</keyword>
  <keyword>pork dialyzed leukocyte extract</keyword>
  <keyword>immunomodulation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make individual participant data available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

